The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- New COVID-19 Drug Shows Greater Promise Against Resistant Viral Strains.
- How a new library is set to transform this underserved N.J. community
- Poll Finds Majority of New Jerseyans Give Negative Ratings to State and National Economy.
- New NJACTS Publication
- One Rule Change Would Help Tens of Thousands of New Jersey Families Pay for Childcare
Categories
- Community (2,243)
- Covid (985)
- CTO Events (6)
- News (2,858)
- Pilots (21)